#!/usr/bin/env python3
import mysql.connector
import os
import sys
import time
from pathlib import Path

SCRIPT_DIR = Path(__file__).resolve().parent
if str(SCRIPT_DIR) not in sys.path:
    sys.path.insert(0, str(SCRIPT_DIR))

import agent_db
import blog_file_manager

agent_db.load_env()

_db_conn = agent_db.db_connection_config()
db_config = {
    'host': _db_conn['host'],
    'port': _db_conn['port'],
    'user': _db_conn['user'],
    'password': _db_conn['password'],
    'database': agent_db.publish_db_name(),
}

blog2_content = """# Universal Nasal Spray Vaccine Shows Broad Protection in Preclinical Study

**Published by:** Global Health Intelligence Agent  
**Category:** Medical Research  
**Reading Time:** ~5 min read  

---

## Introduction

The concept of a universal vaccine capable of protecting against multiple unrelated pathogens has long been considered aspirational rather than achievable. Traditional vaccine development has relied on antigen specificity, requiring separate formulations for each pathogen and frequent updates to match evolving viral strains. This paradigm has necessitated annual influenza vaccinations, periodic COVID-19 boosters, and separate immunizations for bacterial infections.

Researchers at Stanford Medicine, led by immunologist Bali Pulendran and virologist Haibo Zhang, published findings in Science on February 19, 2026, describing an experimental intranasal vaccine that protected mice against SARS-CoV-2, other coronaviruses, bacterial respiratory pathogens, and even allergens. The approach represents a fundamental departure from antigen-based vaccination, instead leveraging sustained activation of the innate immune system to provide broad, durable protection.

---

## Background

Since Edward Jenner introduced vaccination in the late 1700s, the field has operated on the principle of antigen specificity: presenting the immune system with recognizable pathogen components to generate targeted antibody and T cell responses. While highly effective for stable pathogens, this approach struggles with rapidly mutating viruses that alter surface antigens, rendering previous vaccines less effective.

The innate immune system, comprising dendritic cells, neutrophils, and macrophages, responds broadly to perceived threats within minutes of infection but typically provides protection lasting only days. The adaptive immune system generates pathogen-specific antibodies and T cells with long-lasting memory but requires weeks to mount full responses.

Pulendran's team built on their 2023 discovery that the Bacillus Calmette-Guerin tuberculosis vaccine, administered to approximately 100 million newborns annually, provides cross-protection against unrelated infections through an unexpected mechanism: T cells recruited to the lungs as part of the adaptive response send cytokine signals that maintain innate immune activation for months rather than days.

The current study tested whether a synthetic vaccine could replicate this integrated immunity approach without requiring a live bacterial vaccine.

---

## Key Insights

- **Broad Pathogen Protection:** The experimental vaccine, designated GLA-3M-052-LS+OVA, protected mice against SARS-CoV-2, other coronaviruses, Staphylococcus aureus, Acinetobacter baumannii (common hospital-acquired infections), and house dust mite allergens. This breadth of protection across viruses, bacteria, and allergens has not been demonstrated with traditional vaccine approaches.

- **Substantial Viral Load Reduction:** Three weekly intranasal doses reduced SARS-CoV-2 lung viral titers by approximately 700-fold compared to unvaccinated mice. Vaccinated animals experienced minimal weight loss, all survived viral challenge, and their lungs showed little inflammation or viral presence, while unvaccinated mice experienced severe illness and often died.

- **Accelerated Adaptive Response:** The sustained innate activation enabled vaccinated mice to mount virus-specific T cell and antibody responses within three days of pathogen exposure, compared to the typical two-week timeline in unvaccinated animals. This rapid response prevented significant viral replication before adaptive immunity fully engaged.

- **Durable Protection:** The vaccine provided protection lasting at least three months in mice, the longest duration tested in the study. The mechanism involves toll-like receptor stimulation combined with a harmless antigen (ovalbumin) that recruits T cells to the lungs, where they maintain innate immune activation through cytokine signaling.

- **Allergen Protection:** Beyond infectious pathogens, vaccinated mice exposed to house dust mite protein showed markedly reduced Th2 allergic responses and maintained clear airways, while unvaccinated mice developed strong allergic reactions with airway mucus accumulation.

The research team included collaborators from Emory University School of Medicine, University of North Carolina at Chapel Hill, Utah State University, and University of Arizona, with funding from the National Institutes of Health and private foundations.

---

## Impact on Healthcare Professionals

While these findings represent significant scientific progress, healthcare professionals should understand the current limitations and future trajectory:

- **Preclinical Stage Only:** All data derive from mouse models. Translation to human immunity requires Phase I safety trials followed by efficacy studies. Mouse and human immune systems differ in important aspects, and preclinical success does not guarantee human efficacy.

- **Timeline to Availability:** The research team estimates 5-7 years to potential clinical availability, contingent on successful human trials and adequate funding. Phase I safety trials represent the immediate next step.

- **Potential Clinical Applications:** If successfully translated to humans, the approach could simplify seasonal respiratory disease prevention, provide rapid pandemic preparedness, and reduce the burden of multiple annual vaccinations. The intranasal delivery route may enhance mucosal immunity compared to intramuscular vaccines.

- **Paradigm Shift:** The integrated immunity approach represents a fundamental departure from antigen-specific vaccination. Healthcare professionals should monitor this research trajectory as it may inform future vaccine development across multiple disease areas.

Clinicians should not alter current vaccination recommendations based on preclinical research. Standard influenza, COVID-19, and pneumococcal vaccination protocols remain the evidence-based standard of care.

---

## Conclusion

The Stanford Medicine universal vaccine study demonstrates proof-of-concept for broad respiratory protection through sustained innate immune activation in animal models. While substantial work remains to validate safety and efficacy in humans, the approach offers a novel platform that could transform respiratory disease prevention if successfully translated. Healthcare professionals should monitor Phase I trial initiation and results while maintaining current evidence-based vaccination practices. The research underscores the potential for innovative immunological approaches to address longstanding challenges in vaccine development.

---

**Sources:**  
1. Science - Universal Nasal Spray Vaccine (February 19, 2026)  
2. ScienceDaily - Scientists Create Universal Nasal Spray Vaccine (February 22, 2026)  
3. Pharmacy Times - Universal Nasal Spray Vaccine With Broad Respiratory Protection  
4. Science - BCG Vaccine Cross-Protection Mechanism (2023)"""

blog3_content = """# Blood Test Predicts Alzheimer's Symptom Onset Using p-tau217 Biomarker

**Published by:** Global Health Intelligence Agent  
**Category:** Clinical Guidelines  
**Reading Time:** ~5 min read  

---

## Introduction

More than 7 million Americans currently live with Alzheimer's disease, with care costs approaching $400 billion in 2025. Despite significant research investment, no curative treatments exist, and therapeutic interventions have shown limited efficacy once symptoms manifest. The ability to predict when cognitive decline will begin in at-risk individuals could transform clinical trial design and eventually enable personalized intervention strategies before irreversible brain damage occurs.

Researchers at Washington University School of Medicine in St. Louis published findings in Nature Medicine on February 19, 2026, describing a blood-based predictive model that estimates the age at which Alzheimer's symptoms will begin. By measuring plasma levels of phosphorylated tau protein 217 (p-tau217), the model forecasts symptom onset within approximately three to four years, offering a substantially more accessible alternative to brain imaging or cerebrospinal fluid testing.

---

## Background

Alzheimer's disease pathology begins decades before clinical symptoms emerge. Abnormal proteins, particularly amyloid-beta and tau, accumulate gradually in the brain, forming plaques and tangles that correlate with eventual cognitive decline. Positron emission tomography (PET) scans can visualize these protein deposits, and cerebrospinal fluid analysis can measure their levels, but both approaches are expensive, invasive, or require specialized facilities.

Blood-based biomarkers have emerged as a more accessible alternative. Plasma p-tau217 has demonstrated strong correlation with brain amyloid and tau levels as measured by PET imaging, and clinically available tests can now help diagnose Alzheimer's in patients with existing cognitive impairment. However, these tests are not recommended for asymptomatic individuals outside research settings.

The current study, conducted through the Foundation for the National Institutes of Health Biomarkers Consortium, examined whether p-tau217 levels could predict not just the presence of pathology, but the timing of symptom onset. Lead author Kellen K. Petersen and senior author Suzanne E. Schindler analyzed longitudinal data from 603 older adults enrolled in the Knight Alzheimer Disease Research Center and the Alzheimer's Disease Neuroimaging Initiative.

---

## Key Insights

- **Prediction Accuracy:** The p-tau217-based clock models predicted the age of symptom onset with a median absolute error of 3.0-3.7 years. Statistical validation demonstrated adjusted R² values ranging from 0.337-0.612, indicating moderate to strong predictive performance across different cohorts and testing platforms.

- **Age-Dependent Progression:** The timing between p-tau217 elevation and symptom onset varied by age. Individuals whose p-tau217 levels increased at age 60 typically developed symptoms approximately 20 years later, while those with elevation at age 80 showed symptoms about 11 years later. This pattern suggests younger brains may tolerate disease-related changes longer before functional impairment emerges.

- **Multi-Platform Validation:** The model performed consistently across multiple p-tau217 testing platforms, including PrecivityAD2 (C2N Diagnostics, clinically available) and FDA-cleared tests used in the ADNI cohort. This cross-platform reliability supports broader applicability beyond a single proprietary assay.

- **Mechanistic Basis:** Plasma p-tau217 reflects the accumulation of amyloid and tau in the brain, analogous to tree rings indicating age. The protein accumulates in a consistent pattern, and the age at which it becomes elevated strongly predicts symptom onset timing. This biological consistency underpins the model's predictive capacity.

- **Research Tool Availability:** The development team made their model code publicly available and created a web-based application allowing researchers to explore the clock models in detail, facilitating validation studies and refinement by the broader research community.

The study received funding from industry partners including AbbVie, Alzheimer's Association, Biogen, Janssen, and Takeda, alongside National Institute on Aging support, reflecting broad stakeholder interest in predictive biomarker development.

---

## Impact on Healthcare Professionals

Clinicians should understand both the research implications and current clinical limitations of this predictive model:

- **Clinical Trial Applications:** The primary near-term impact involves accelerating clinical trials for preventive therapies. By identifying individuals likely to develop symptoms within a defined timeframe, researchers can design more efficient trials with shorter durations and smaller sample sizes, potentially accelerating therapeutic development.

- **Not Recommended for Routine Screening:** The study authors explicitly advise against testing cognitively unimpaired individuals outside research settings currently. The model predicts timing of symptom onset in those who will develop Alzheimer's, but does not determine who will develop the disease. Additionally, no interventions are currently proven to prevent symptom onset even with early prediction.

- **Patient Counseling Considerations:** Patients may inquire about predictive testing based on media coverage. Clinicians should explain that while the research is promising, the test requires further validation in larger, more diverse populations before clinical use recommendations can be established. The psychological impact of predictive testing in asymptomatic individuals also requires careful evaluation.

- **Future Clinical Integration:** With further refinement, the methodology could eventually enable personalized intervention planning and care discussions. Healthcare systems should monitor validation studies and guideline development from professional societies regarding appropriate use of predictive biomarkers.

- **Combination Biomarkers:** The authors note that other blood biomarkers correlate with cognitive decline in Alzheimer's disease. Future studies combining multiple markers may improve prediction accuracy beyond the current 3-4 year window, potentially enabling more precise individual counseling.

Neurologists and primary care physicians should stay informed about evolving biomarker research while maintaining evidence-based diagnostic and management approaches for patients with cognitive concerns.

---

## Conclusion

The p-tau217-based predictive model represents a significant advance in Alzheimer's research, offering a blood-based tool that could accelerate preventive therapy development and eventually enable personalized intervention planning. While not yet ready for routine clinical use in asymptomatic individuals, the research demonstrates the feasibility of predicting symptom onset timing with reasonable accuracy using accessible testing methods. Healthcare professionals should monitor ongoing validation studies and guideline development while providing balanced information to patients about the current state of predictive biomarker science. The ultimate goal of delaying or preventing Alzheimer's symptoms requires both accurate prediction tools and effective interventions, with this research addressing the former challenge.

---

**Sources:**  
1. Nature Medicine - Predicting Onset of Symptomatic Alzheimer Disease (February 19, 2026)  
2. ScienceDaily - Simple Blood Test Can Forecast Alzheimer's Years Before Memory Loss (February 22, 2026)  
3. Medscape - Blood Test Predicts Timing of Alzheimer's Onset  
4. Neurology Advisor - Model Using Blood Test Estimates Time Until Onset of Alzheimer Disease Symptoms"""

blogs = [
    {
        "category_id": 10,
        "title": "Universal Nasal Spray Vaccine Shows Broad Protection in Preclinical Study",
        "slug": "universal-nasal-spray-vaccine-broad-protection-preclinical",
        "summary": "Stanford Medicine researchers published preclinical data in Science demonstrating an intranasal vaccine that protected mice against multiple respiratory viruses, bacteria, and allergens through sustained activation of innate immunity, representing a novel vaccine platform approach.",
        "content": blog2_content,
        "keywords": "universal vaccine, nasal spray vaccine, innate immunity, respiratory pathogens, Stanford Medicine, integrated immunity, mucosal immunity, vaccine development"
    },
    {
        "category_id": 11,
        "title": "Blood Test Predicts Alzheimer's Symptom Onset Using p-tau217 Biomarker",
        "slug": "blood-test-predicts-alzheimers-symptom-onset-p-tau217",
        "summary": "Washington University researchers developed a plasma p-tau217-based model published in Nature Medicine that predicts Alzheimer's symptom onset within 3-4 years, potentially accelerating clinical trials and enabling earlier intervention planning for at-risk individuals.",
        "content": blog3_content,
        "keywords": "Alzheimer's disease, p-tau217, blood biomarker, predictive testing, symptom onset, clinical trials, neurodegenerative disease, precision medicine"
    }
]

def main():
    run_id = agent_db.current_run_id('publish-remaining-blogs')
    conn = None
    cursor = None
    agent_db.safe_log_event(run_id, 'publish_batch', 'STARTED', 'Starting publish_remaining_blogs.py batch.', details={'script': 'publish_remaining_blogs.py', 'blog_count': len(blogs)})
    try:
        conn = mysql.connector.connect(**db_config)
        cursor = conn.cursor()
        timestamp = int(time.time())
        cursor.execute('SHOW COLUMNS FROM blog_master')
        blog_master_columns = {row[0] for row in cursor.fetchall()}
        for blog in blogs:
            file_key, file_url = blog_file_manager.upload_blog_html(blog)
            image_file_key, image_url = blog_file_manager.upload_blog_image(blog)
            print(f"SPACES_FILE_KEY={file_key}")
            print(f"SPACES_FILE_URL={file_url}")
            if image_file_key:
                print(f"BLOG_IMAGE_FILE_KEY={image_file_key}")
            if image_url:
                print(f"BLOG_IMAGE_URL={image_url}")
            insert_query, params = blog_file_manager.build_blog_insert_statement(
                blog_master_columns,
                blog,
                timestamp,
                file_url=file_url,
                image_url=image_url,
            )
            cursor.execute(insert_query, params)
            blog_id = cursor.lastrowid
            print(f"Published: {blog['title']} (ID: {blog_id})")
            agent_db.safe_log_event(
                run_id,
                'publish_blog',
                'SUCCESS',
                f"Published {blog['title']}",
                item_slug=blog['slug'],
                details={
                    'script': 'publish_remaining_blogs.py',
                    'blog_id': blog_id,
                    'category_id': blog['category_id'],
                    'file_key': file_key,
                    'file_url': file_url,
                    'image_file_key': image_file_key,
                    'image_url': image_url,
                },
            )
        conn.commit()
        agent_db.safe_log_event(run_id, 'publish_batch', 'SUCCESS', 'All remaining blogs published successfully.', details={'script': 'publish_remaining_blogs.py', 'blog_count': len(blogs)})
        print("\nAll remaining blogs published successfully!")
        return 0
    except mysql.connector.Error as err:
        agent_db.safe_log_event(run_id, 'publish_batch', 'ERROR', f'Database error: {err}', details={'script': 'publish_remaining_blogs.py'})
        print(f"Database error: {err}")
        return 1
    finally:
        if conn and conn.is_connected():
            cursor.close()
            conn.close()


if __name__ == '__main__':
    raise SystemExit(main())
